<div id="readability-page-1"><div><p>uniQure (QURE) is in focus after first quarter results showed revenue of US$3.56 million and a net loss of US$53.54 million, alongside fresh regulatory progress for its Huntington’s disease gene therapy, AMT-130.</p> <p>See our latest analysis for uniQure.</p> <p>The stock has reacted strongly to the recent earnings update and regulatory progress on AMT-130, with a 1-month share price return of 79.84% and a 1-year total shareholder return of 110.34%, which may indicate building momentum rather than a short-lived bounce.</p> <p>If uniQure’s move has your attention, this can be a moment to expand your watchlist with other healthcare opportunities, including gene therapy and neurology focused companies, via 34 healthcare AI stocks</p> <p>After such a sharp move and with analysts’ price targets still above the current US$27.66 share price, the key question is whether uniQure is still trading below its potential or if the market is already pricing in future growth.</p> <h2>Most Popular Narrative: 28.1% Undervalued</h2> <p>Against the last close of $27.66, the most followed narrative points to a fair value of $38.48, which assumes a high bar for future performance and regulatory success.</p> <blockquote> <p><em>The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition.</em></p> <p><em>Expansion of the clinical pipeline with new studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS could lead to additional revenue streams if these treatments are successful and commercialized.</em></p> </blockquote> <p>Read the complete narrative.</p> <p>The fair value hinges on rapid revenue expansion, a sharp swing in profit margins, and a future earnings multiple usually reserved for standout growth stories. Curious which assumptions drive that outcome and how sensitive the valuation is to shifts in trial success and timelines? The narrative lays out the full set of moving parts and how they add up to that price target.</p> <p><strong>Result: Fair Value of $38.48 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, the fair value case still leans heavily on AMT-130’s regulatory path, while revenue pressure and a shift to external manufacturing could both unsettle that story.</p> <p>Find out about the key risks to this uniQure narrative.</p> <h2>Next Steps</h2> <p>With such a mixed set of signals, it helps to move quickly and stress test the upside and downside for yourself using our breakdown of 1 key reward and 4 important warning signs.</p> <h2>Looking for more investment ideas?</h2> <p>If uniQure is on your radar, do not stop here. Broaden your opportunity set with focused stock lists that match clear, thoughtful criteria.</p> <ul> <li>Target potential value opportunities by scanning companies that screen well on quality and pricing using 49 high quality undervalued stocks.</li> <li>Prioritise resilience by reviewing stocks that combine defensive characteristics with low risk scores via 71 resilient stocks with low risk scores.</li> <li>Hunt for lesser known opportunities by checking a screener containing 21 high quality undiscovered gems.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if uniQure might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

QURE

IBBQ

SBIO

LABU

<p>uniQure (QURE) reported Q1 revenue of $3.56 million and a net loss of $53.54 million, alongside progress on its AMT-130 gene therapy for Huntington's disease. The stock surged 79.84% in a month and 110.34% over the year, suggesting strong momentum. Analysts value the stock at $38.48, indicating it may be undervalued at the current price of $27.66. Future revenue growth hinges on AMT-130's regulatory success and expansion into new treatments. Investors are advised to consider both potential rewards and risks before making decisions.</p>

Simplywall

Uniqure

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

A Look At uniQure (QURE) Valuation After Q1 Results And AMT-130 Regulatory Progress